29
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence of Osteoporosis and Fracture in China : The China Osteoporosis Prevalence Study

      research-article
      , MD 1 , , MD 2 , , MD 3 , , MD 4 , , PhD 3 , , MD 4 , , MS 3 , , PhD 5 , , MD 2 , , MD 6 , , MD 7 , , PhD 8 , , MPH 9 , , BS 10 , , MS 11 , , MS 12 , , MPH 13 , , BS 14 , , MD 15 , , MD 16 , , MD 17 , , MS 18 , , BS 19 , , MD, PhD 20 , , MD 21 , , MS 22 , , MS 23 , , MS 24 , , MD 25 , , MD 26 , , MD 27 , , MPA 1 , , , MD 4 ,
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This cross-sectional study evaluates the prevalence of and factors associated with osteoporosis, clinical fractures, and vertebral fractures among adults 40 years or older in mainland China by sex, age group, and urban vs rural residence.

          Key Points

          Question

          What is the prevalence of osteoporosis and clinical and vertebral fracture in the adult population of mainland China?

          Findings

          In this cross-sectional study of 20 416 individuals, the prevalence of osteoporosis among adults 40 years or older was 5.0% among men and 20.6% among women, and the prevalence of vertebral fracture was 10.5% among men and 9.7% among women.

          Meaning

          These findings suggest that recommendations for screening and treatment of fractures should include both men and women in China.

          Abstract

          Importance

          The aging of the population is associated with an increasing burden of fractures worldwide. However, the epidemiological features of fractures in mainland China are not well known.

          Objective

          To assess the prevalence of and factors associated with osteoporosis, clinical fractures, and vertebral fractures in an adult population 40 years or older in mainland China.

          Design, Setting. and Participants

          This cross-sectional study, the China Osteoporosis Prevalence Study, was conducted from December 2017 to August 2018. A random sample of individuals aged 20 years or older who represented urban and rural areas of China were enrolled, with a 99% participation rate.

          Main Outcomes and Measures

          Weighted prevalence of osteoporosis, clinical fracture, and vertebral fracture by age, sex, and urban vs rural residence as determined by x-ray absorptiometry, questionnaire, and radiography.

          Results

          A total of 20 416 participants were included in this study; 20 164 (98.8%; 11 443 women [56.7%]; mean [SD] age, 53 [13] years) had a qualified x-ray absorptiometry image and completed the questionnaire, and 8423 of 8800 (95.7%) had a qualified spine radiograph. The prevalence of osteoporosis among those aged 40 years or older was 5.0% (95% CI, 4.2%-5.8%) among men and 20.6% (95% CI, 19.3%-22.0%) among women. The prevalence of vertebral fracture was 10.5% (95% CI, 9.0%-12.0%) among men and 9.7% (95% CI, 8.2%-11.1%) among women. The prevalence of clinical fracture in the past 5 years was 4.1% (95% CI, 3.3%-4.9%) among men and 4.2% (95% CI, 3.6%-4.7%) among women. Among men and women, 0.3% (95% CI, 0.0%-0.7%) and 1.4% (95% CI, 0.8%-2.0%), respectively, with osteoporosis diagnosed on the basis of bone mineral density or with fracture were receiving antiosteoporosis treatment to prevent fracture.

          Conclusions and Relevance

          In this cross-sectional study of an adult population in mainland China, the prevalence of osteoporosis and vertebral fracture were high and the prevalence of vertebral fracture and clinical fracture was similarly high in men and women. These findings suggest that current guidelines for screening and treatment of fractures among patients in China should focus equally on men and women and should emphasize the prevention of vertebral fractures.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Clinician’s Guide to Prevention and Treatment of Osteoporosis

          The Clinician’s Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            European guidance for the diagnosis and management of osteoporosis in postmenopausal women

            Summary Guidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk from fractures due to osteoporosis. Introduction The International Osteoporosis Foundation and European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of osteoporosis in 2013. This manuscript updates these in a European setting. Methods Systematic reviews were updated. Results The following areas are reviewed: the role of bone mineral density measurement for the diagnosis of osteoporosis and assessment of fracture risk; general and pharmacological management of osteoporosis; monitoring of treatment; assessment of fracture risk; case-finding strategies; investigation of patients; health economics of treatment. The update includes new information on the evaluation of bone microstructure evaluation in facture risk assessment, the role of FRAX® and Fracture Liaison Services in secondary fracture prevention, long-term effects on fracture risk of dietary intakes, and increased fracture risk on stopping drug treatment. Conclusions A platform is provided on which specific guidelines can be developed for national use.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vertebral fracture assessment using a semiquantitative technique.

              The assessment of vertebral fracture by conventional radiography has been refined and improved using either semiquantitative or quantitative criteria. The inter- and intraobserver variability was determined for a semiquantitative visual approach that we routinely use in clinical studies for assessing prevalent and incident vertebral fractures. In addition, the semiquantitative approach was compared with a quantitative morphometric approach. The incidence and prevalence of vertebral fractures were determined in 57 postmenopausal women (age 65-75 years) by three independent observers. The radiographic basis for fracture definitions and the source of interobserver agreement for the semiquantitative technique. We conclude that the semiquantitative approach can be applied reliably in vertebral fracture assessment when performed using well-defined criteria.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                16 August 2021
                August 2021
                16 August 2021
                : 4
                : 8
                : e2121106
                Affiliations
                [1 ]National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
                [2 ]Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                [3 ]Division of Elderly Health, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
                [4 ]Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                [5 ]Medical Sciences Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
                [6 ]Department of Wound Repair and Rehabilitation Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, Army Medical University, Chongqing, China
                [7 ]Department of Orthopaedics, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, China
                [8 ]Department of Endocrinology, Chengdu Military General Hospital, Chengdu, Sichuan Province, China
                [9 ]Beijing Center for Diseases Prevention and Control, Beijing, China
                [10 ]Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, Shanxi Province, China
                [11 ]Jilin Provincial Center for Disease Control and Prevention, Changchun, Jilin Province, China
                [12 ]Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, China
                [13 ]Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang Province, China
                [14 ]Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei Province, China
                [15 ]Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan Province, China
                [16 ]Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong Province, China
                [17 ]Sichuan Center for Disease Control and Prevention, Chengdu, Sichuan Province, China
                [18 ]Chongqing Center for Disease Control and Prevention, Chongqing, China
                [19 ]Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, Shaanxi Province, China
                [20 ]Hunan Provincial Key Laboratory of Metabolic Bone Diseases, National Clinical Research Center for Metabolic Diseases, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China
                [21 ]Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China
                [22 ]Department of Endocrinology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial Geriatrics Institute, Guangzhou, Guangdong Province, China
                [23 ]Department of Osteoporosis, Jilin FAW General Hospital, Changchun, Jilin Province, China
                [24 ]Center of Osteoporosis, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, China
                [25 ]Department of Osteoporosis, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi Province, China
                [26 ]Department of Endocrinology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
                [27 ]San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, California
                Author notes
                Article Information
                Accepted for Publication: June 10, 2021.
                Published: August 16, 2021. doi:10.1001/jamanetworkopen.2021.21106
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Wang L et al. JAMA Network Open.
                Corresponding Authors: Weibo Xia, MD, Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China ( xiaweibo8301@ 123456163.com ); Zhixin Li, MPA, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, No. 27 Nanwei Rd, Xicheng District, Beijing 100050, China ( lizhixin@ 123456ncncd.chinacdc.cn ).
                Author Contributions: Drs Wang, Yu, Yin, and Lijia Cui contributed equally as first authors. Dr Xia and Mr Li had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Wang, Yu, Yin, Ying, Li, Xia.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Wang, Yu, Yin, Lijia Cui, Jiang, Ying, Li, Xia.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Yin, Lijia Cui, Tang, Jiang, Lu Cui, Zhao.
                Obtained funding: Wang, Yu, M. Zhang, Ying, Li, Xia.
                Administrative, technical, or material support: Yu, Yin, Q. Lin, H. Lin, Liu, Ding, M. Zhang, Ying, Li, Xia.
                Supervision: H. Lin, M. Zhang, Cummings, Li, Xia.
                Conflict of Interest Disclosures: Drs Wang, Yu, Yin, Lijia Cui, Tang, and Jiang; Ms Lu Cui; Drs Zhao, Q. Lin, Chen, H. Lin, and Jin; Ms Z. Dong; Ms Ren; Mr Hou; Ms Y. Zhang; Mr Zhong; Mr Cai; Drs Liu, Meng, and Deng; Mr Ding; Drs Ma and Xie; Mr Wu; Ms M. Zhang; Drs Zeng and J. Dong; Mr Li; and Dr Xia reported receiving grants from the Chinese Central Government Key Project of Public Health Program and grants from the Chinese Red Cross Foundation during the conduct of the study. No other disclosures were reported.
                Funding/Support: This project was funded by the Chinese Central Government Key Project of Public Health Program (grant [2018]8) and the Chinese Red Cross Foundation.
                Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Chinese Center for Disease Control and Prevention.
                Meeting Presentation: This paper was presented at the 9th International Conference on Osteoporosis and Bone Research; October 18, 2018; Suzhou, Jiangsu, China.
                Article
                zoi210622
                10.1001/jamanetworkopen.2021.21106
                8369359
                34398202
                2f8167ca-9cab-4af5-9d4d-81f272514109
                Copyright 2021 Wang L et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 7 May 2021
                : 10 June 2021
                Categories
                Research
                Original Investigation
                Online Only
                Diabetes and Endocrinology

                Comments

                Comment on this article